RenovoRx CEO to Share Insights at Global Investment Conference
![RenovoRx CEO to Share Insights at Global Investment Conference](https://investorshangout.com/images/blog/ihnews-RenovoRx%20CEO%20to%20Share%20Insights%20at%20Global%20Investment%20Conference.jpg)
RenovoRx CEO to Present at Global Investment Conference
LOS ALTOS, Calif., Aug. 27, 2024 — RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company known for developing innovative precision oncology therapies through a local drug-delivery platform, has announced that CEO Shaun Bagai will present at H.C. Wainwright’s 26th Annual Global Investment Conference. This event will take place at a prestigious venue in New York City from September 9-11, 2024, with Mr. Bagai's presentation scheduled for September 9, 2024, at 7:00 a.m. ET.
During his presentation, Mr. Bagai will highlight the company’s recent corporate achievements, particularly the advancements in RenovoRx’s pivotal ongoing Phase III TIGeR-PaC clinical trial. This trial is essential for evaluating the company’s proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform aimed at treating Locally Advanced Pancreatic Cancer (LAPC).
Details of the Presentation
Date: Monday, September 9, 2024
Time: 7:00 a.m. ET
Location: Lotte New York Palace Hotel, New York City
Speaker: Shaun Bagai, CEO
Significance of TIGeR-PaC Clinical Trial
Mr. Bagai will also provide insights into RenovoRx's ongoing exploration of new commercial opportunities linked to its proprietary therapy platform technology, particularly the FDA-cleared RenovoCath delivery system, facilitating stand-alone device potential. The RenovoCath device is indicated for temporary vessel occlusion in various medical procedures, including arteriography and chemotherapeutic drug infusion. Notably, in connection with its commercial strategy, RenovoRx appointed Ryan Witt as Senior Vice President of Corporate Strategy and Partnerships in June 2024.
About RenovoRx's Clinical Innovations
RenovoRx is conducting the TIGeR-PaC clinical trial as a Phase III randomized multi-center study, assessing the TAMP™ platform specifically for LAPC treatment. This trial employs RenovoRx’s first product candidate that utilizes TAMP technology, representing a novel investigational oncology drug-delivery system incorporating the FDA-cleared RenovoCath device for administering the chemotherapy agent gemcitabine HCl directly.
Interim Analysis and Future Insights
The first interim analysis of the Phase III trial was finalized in March 2023. Encouragingly, the Data Monitoring Committee recommended the study's continuation, emphasizing the importance of TAMP technology for patients suffering from LAPC. The study aims for a primary endpoint that includes achieving a six-month overall survival benefit while focusing on minimizing side effects when compared to standard treatments. The timing for the second interim analysis is expected to align with the estimated 52nd event, projected to occur late in 2024 or early 2025.
RenovoRx: Company Overview
RenovoRx is dedicated to developing advanced precision oncology solutions using a unique local drug delivery mechanism designed to meet significant unmet medical needs. The TAMP™ therapy platform effectively delivers treatment directly to the tumor site, enhancing therapeutic impacts while potentially reducing the associated toxicities compared to systemic IV therapy. The company's robust pipeline includes a Phase III lead product candidate that is currently part of a U.S. investigational new drug application overseen by regulatory authorities.
In addition to its core clinical activities, RenovoRx is actively pursuing commercialization avenues utilizing its TAMP technology and the RenovoCath delivery system independent of other oncology applications. RenovoRx remains committed to innovatively transforming cancer care and enhancing patient lives through groundbreaking therapeutic solutions.
Frequently Asked Questions
What will RenovoRx CEO Shaun Bagai present at the conference?
Mr. Bagai will discuss the company's recent accomplishments and details about its TIGeR-PaC clinical trial focused on treating locally advanced pancreatic cancer.
Where and when is the conference being held?
The H.C. Wainwright’s Global Investment Conference will occur from September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.
What is the significance of the TIGeR-PaC trial?
The TIGeR-PaC trial evaluates the efficacy of the TAMP™ therapy platform in improving treatment outcomes for patients with locally advanced pancreatic cancer.
Who was recently appointed to RenovoRx's Corporate Strategy team?
Ryan Witt was appointed as Senior Vice President of Corporate Strategy and Partnerships in June 2024.
What does the RenovoCath device do?
The RenovoCath device is utilized for temporary vessel occlusion in medical procedures such as arteriography, preoperative occlusion, and chemotherapy drug infusion.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Pasithea Therapeutics to Present at Investment Conference
- Shuttle Pharma Meets Nasdaq Compliance for Stock Listing
- Taboola Launches Maximize Conversions AI Tool for Advertisers
- Interlink Electronics to Present at Annual Gateway Conference
- ARKO Corp. Expands Presence with New Handy Mart Store
- BEN Appoints Healthcare Leader Richard S. Isaacs to Board
- GitLab CFO Brian Robins to Speak at Piper Sandler Conference
- Verizon and Skylo Partner for Direct-to-Device Messaging
- Editas Medicine to Present at Major Investor Conferences
- Kura Sushi USA's Upcoming Investor Conferences for Engagement